GlassScriptPhysician profile
John P Norris
NPI 1346357779
$4,293.70
in general payments reported to CMS, 2019-2025
29 companies · $442 in 2025
The $442 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,930 · 2020: $117 · 2022: $636 · 2023: $655 · 2024: $515 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,597.60 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $1,512.20 | 2019-2022 | |
| Abbvie INC. | $587.16 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $336.20 | 2019-2025 | |
| Coopersurgical, INC. | $256.25 | 2022-2025 | Endosee, Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $235.88 | 2020-2025 | Slynd |
| Mayne Pharma Commercial LLC | $230.27 | 2022-2025 | |
| Astellas Pharma US INC | $179.29 | 2022-2025 | Veozah |
| Hologic Sales and Service, LLC | $155.39 | 2019-2024 | Novasure |
| Pfizer INC. | $122.59 | 2022-2025 | |
| Millicent US INC | $92.70 | 2024-2025 | Femlyv, Intrarosa |
| Therapeuticsmd, INC. | $91.08 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.39 | 2022 | |
| Exact Sciences Corporation | $61.78 | 2023-2024 | Cologuard Collection Kit |
| Roche Diagnostics Corporation | $45.74 | 2019-2020 | |
| Ethicon US, LLC | $36.56 | 2023 | Echelon Circular, Echelon Flex, Endopath |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $28.16 | 2025 | Zurzuvae |
| Kerecis Limited | $28.13 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vertical Pharmaceuticals, LLC | $26.35 | 2019-2020 | |
| Medtronic, INC. | $23.71 | 2022 | |
| Octapharma USA, INC. | $22.41 | 2025 | Fibryga |
| Sanofi Pasteur INC. | $21.35 | 2024 | |
| Daiichi Sankyo INC. | $19.87 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.24 | 2019 | |
| Avion Pharmaceuticals | $16.63 | 2023 | Balcoltra |
| Becton, Dickinson and Company | $15.38 | 2025 | |
| Organon LLC | $15.21 | 2024 | |
| Covidien LP | $12.03 | 2019 | |
| Mission Pharmacal Company | $11.41 | 2019 | |
| Avanos Medical | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.